Explore
Swab and Send
Fundraising is integral to citizen science 'Swab and Send' initiative, which...
Public Engagement
Clinical Diagnostic Parasitology Laboratory
The Clinical Diagnostic Parasitology laboratory is a UKAS accredited laboratory...
Webinar: ResistanceSim - A Game Changer for Training in Insecticide Resistance Management: Stories from the Field
JOIN US ONLINE A Game Changer for Training in Insecticide Resistance Management...
Menu

Professor Shabbar Jaffar

Head, Dept of International Public Health, Chair of Epidemiology and Global Health

Joined LSTM on 1st July 2015. Previously Professor of Epidemiology at the London School of Hygiene and Tropical Medicine (LSHTM).

Lived in The Gambia (3-years), Uganda (6 months), South Africa (12 months – on sabbatical) and Malawi (6 months).

  • FRCP (2011, Edinburgh) (non-clinical fellow)
  • PhD Epidemiology (2001, LSHTM),
  • MSc Biometry (1990, Reading University).

Mostly global health trials of management strategies for HIV-infection and associated co-infections.

Co-PI on trial of home care versus facility care (Lancet 2009) and trial evaluating co-infection screening and adherence support among HIV-infected people with advanced disease (Lancet 2015).

Co-applicant on an MRC phase III trial of cryptococcal meningitis treatment strategies and on a Wellcome Trust funded strategic award on tackling the rising incidence of non-communicable diseases in Africa.

Research grants:

Wellcome Trust Malawi Epidemiology and Intervention Research Unit: addressing public health research. priorities through partnership. £5,000,000. 2012 to 2016. Strategic Award (co-applicant).

EDCTP (European and Developing Countries Clinical Trials Partnership). Approximately £3m. Reduction of early mortality among HIV-infected subjects starting antiretroviral therapy in Tanzania and Zambia: a randomised trial (The REMSTART trial). co-PI. 2011 – 2015

UK Medical Research Council. A phase III randomised controlled trial of oral fluconazole plus flucytosine versus amphotericin B-based therapy for one or two weeks for initial treatment of HIV-associated cryptococcal meningitis. Approx £3.0m. Role: co-applicant (PI Prof Tom Harrison, St Georges Medical School University of London).   2011-2017

US Centers for Disease Control and Prevention (CDC). Approximately £2.5m. Cluster -randomised trial to compare the effectiveness of home-based compared with facility-based delivery of antiretroviral therapy in Jinja, South-East Uganda. Role co-PI. 2004 - 2009 

Other relevant expertise, professional memberships etc.:

Panel member, Global Health (UF-5), Swedish Research Council (2015 -

Chair, EDCTP Scientific Advisory Committee (2008-2013).

Joint Editor, Tropical Medicine and International Health (2004 – 2015)

Selected publications

    1. Mfinanga S, Chanda D, Lesikari S, Guinness L, Bottomley C, Chijoka C, Masasi A, Kimaro G, Ngowi B, Kahwa B, Mwaba P, Harrison TS, Egwaga S, Jaffar S . Cryptococcal meningitis screening and community-based early adherence support reduces all-cause mortality among HIV-infected people initiating antiretroviral therapy with advanced disease: a randomised-controlled trial in Tanzania and Zambia. The Lancet 2015; 385: 2173 – 82 (fast track)
    1. Lazarus JV, Safreed-Harmon K, Nicholson J, Jaffar, S. Health service delivery models for the provision of antiretroviral therapy in sub-Saharan Africa: a systematic review. Trop Med Int Health. 2014;19(10):1198-215.
    1. Joseph N, Tihana Bicanic, Angela Loyse, Daniel Namarika, Arthur Jackson, Jesse C Nussbaum, Nicky Longley, Conrad Muzoora, Jacob Phulusa, Kabanda Taseera, Creto Kanyembe, Douglas Wilson, Mina C Hosseinipour, Anne-Marie E Brouwer, Direk Limmathurotsakul, Nicholas White, Charles van der Horst, Robin Wood, Graeme Meintjes, John Bradley, Shabbar Jaffar and Thomas Harrison. Determinants of Mortality in a Combined Cohort of 501 Patients with HIV-associated Cryptococcal Meningitis: Implications for Improving Outcomes. Clin Infect Dis 2014; 58: 736-745
    1. Woodd SL, Grosskurth H, Levin J, Amuron B, Namara G, Birunghi J, Coutinho A, Jaffar S. Home-based versus clinic-based care for patients starting antiretroviral therapy with low CD4 counts in Uganda: findings from a cluster-randomised trial. AIDS 2014, 28: 569-76.
    1. Atun R, Jaffar S, Nishtar S, Knaul FM, Barreto ML, Nyirenda M, Banatvala N, Piot P. Improving responsiveness of health systems to non-communicable diseases. Lancet. 2013; 381: 690-7.
    1. Ebrahim S, Pearce N, Smeeth L, Casas JP, Jaffar S, Piot P. Tackling non-communicable diseases in low- and middle-income countries: is the evidence from high-income countries all we need? PLoS Med. 2013;10(1):e1001377. doi: 10.1371/journal.pmed.1001377.
    1. Jackson AT, Nussbaum JC, Phulusa J, Namarika D, Chikasema M, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, van der Horst C, Harrison TS. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS. 2012; 26:1363-70.
    1. Wamoyi J, Mbonye M, Seeley J, Birungi J, Jaffar S. Changes in sexual desires and behaviours of people living with HIV after initiation of ART: implications for HIV prevention and health promotion. BMC Public Health. 2011; 11:633
    1. Allen C, Mbonye M, Seeley J, Birungi J, Wolff B, Coutinho A, Jaffar S. ABC for people with HIV: responses to sexual behaviour recommendations among people receiving antiretroviral therapy in Jinja, Uganda. Curr Health Sex 2011; 13:529-43
    1. Amuron B, Levin J, Birunghi J, Namara G, Coutinho A, Grosskurth H, Jaffar S. Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study. AIDS Res Ther. 2011; 8: 39.
    1. Gladstone B, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman, AM, Jaffar S, Gomara MI, Gray JJ, Brown DWG, Desselberger U, Crawford SE, John J, Babji S, Estes MK, Kang G. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med. 2011;365: 337-46.

     

    1. Lugada E, Levin J, Abang B, Mermin J, Mugalanzi E, Namara G, Gupta S, Grosskurth H, Jaffar S, Coutinho A, Bunnell R. Comparison of home and clinic-based hiv testing among household members of persons taking antiretroviral therapy in uganda: results from a randomized trial. J Acquir Immune Defic Syndr. 2010 Oct 1;55(2):245-52.
    1. Jaffar S, Amuron B, Foster S, Birungi J, Levin J, Namara G, Nabiryo G, Ndembi N, Kyomuhangi R,  Opio A, Bunnell R, Tappero JW,  Mermin J, Coutinho A, and Grosskurth  H on behalf of the Jinja trial team. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. The Lancet 2009; 374: 2080-9.
    1. Institute of Medicine (IOM). 2008. Methodological challenges in biomedical HIV prevention trials. Washington, DC: The National Academies Press. (www.iom.edu/hivpreventiontrials) (peer-reviewed book). Editors: Stephen W. Lagakos and Alicia R. Gable. Committee: Stephen Lagakos, Harvey J. Alter, Ronald Bayer, Solomon Benatar, Ronald Brookmeyer, Carlos del Rio, David Feigal, Els Goetghebeur, Laura A. Guay, Sally Hodder, Shabbar Jaffar, Edward K. Kirumira, George Rutherford, Olive Shisana, Gina Wingood.
    1. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA; Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005; 365: 1139-46 [Fast track]
    1. Jaffar S, Grant A, Whitworth J, Smith PG and Whittle H. The natural history of HIV-1, HIV-2 and dual infections in adults in Africa.  Bulletin WHO 2004; 82: 462-9.
    1. The Lapdap clinical trial team (Alloueche A, Bailey W, Bwika J, Chimpeni P, Falade CO, Fehintola FA, Jaffar S, Horton J, Kanyok T, Kremsner PG, Kublin JG, Lang T, Mkandala  C, Missinou MA, Premji Z, Robertson L, Ward SA, Winstanley PA. A double-blind randomised comparison of chlorproguanil-dapsone (LapdapTM) with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young children. Lancet 2004; 363: 1843-8
    1. Jaffar S, Leach A, Smith P, Cutts F, Greenwood BM. Effects of misclassification of causes of death on the power of a trial to assess the efficacy of a pneumococcal conjugate vaccine in The Gambia. Int J Epidemiol 2003; 32: 430-6.
    1. Jiamton S, Pepin J, Suttent R, Filteau S, Mahakkanukrauh B, Hanshaoworakul W, Chaisilwattana P, Suthipinittharm P, Shetty P and Jaffar S. A randomised placebo controlled trial of the impact of multiple micronutrient supplementation on disease progression and mortality among HIV-1 infected Thai individuals. AIDS 2003; 17: 2461-2469